The effect of biological anti-TNF-α therapy, originator and biosimilar, used to treat ankylosing spondylitis was studied based on clinical and blood counts and an inflammatory marker
Main Article Content
Keywords
ankylosing spondylitis, anti-TNF therapy, clinical signe, blood counts . inflammatory marker
Abstract
Ankylosing spondylitis (AS) is a common inflammatory rheumatic disease that affects the axial skeleton. It causes inflammatory back pain, structural and functional problems, and a lower quality of life. If an AS patient does not respond to NSAIDs, the FDA has approved several anti-TNF therapy originators and biosimilars. This study aims to determine how well anti-TNF treats ankylosing spondylitis using a traditional complete blood count, clinical signs, and inflammatory markers. Blood samples were collected from 81 AS patients from two groups: 67 AS patients treated with anti-TNF therapy and 14 newly diagnosed patients who were not given treatment (naïve); in addition, 65 healthy individuals were enrolled in the study as a control group. The complete blood count showed a significant difference between the three groups in lymphocyte, neutrophil, and platelet counts (P = 0.001). Positive controls (14/14) treated with NSAIDs had higher disease activity than established patients (32/67) treated with an anti-TNF drug (P = 0.0001). There is a higher significant difference in inflammatory markers between patients with AS and positive controls than in healthy individuals (p = 0.001). In conclusion, AS patients had decreased activity with anti-TNF therapy but progressed on radiographic examination.
References
2. Kraag G, Stokes B, Groh J, Helewa A, Goldsmith C. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis—a randomized controlled trial. J Rheumatol 1990; 17: 228–33.
3. Wanders A, Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52: 1756–65.
4. Kirchhoff, C.F.; Wang, X.Z.M.; Conlon, H.D.; Anderson, S.; Ryan, A.M.; Bose, A. Biosimilars: Key regulatory considerations and similarity assessment tools. Biotechnol. Bioeng. 2017; 114: 2696–2705. [PubMed].
5. Department of Health and Human Services Office of the Secretary. 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program. 2020. Accessed at
https://www.govinfo.gov/content/pkg/FR-2020-05-01/pdf/2020- 07419.pdf (www.govinfo.gov/content/pkg/FR-2020-05-01/pdf/2020-07419.pdf)7 on October 18, 2021.
6. Garrett S, Jenkinson T, Kennedy LG et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286-91.
7. Jung-Hwan Son, Sang-Won Cha. Anti-TNF-α Therapy for Ankylosing Spondylitis. Clinics in Orthopedic Surgery 2010;2:28-33.
8. D. N. Hull, R. O. Williams, E. Pathan, et al. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of 144 inflammatory arthritis. Clinical and Experimental Immunology.2015; 181: 401– 406.
9. Jimenez-Gomez, Y; Lopez-Pedrera, C; Font, P; Ruiz-Limon, P; PerezSanchez, C; et al. Role of Leukocyte Subsets in the Inflammation, Oxidative Stress and Bone Turnover in Ankylosing Spondylitis Patients. Annals of the Rheumatic Diseases, suppl. 2; London.2015; 74: 493.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.